Fraught with Treatment Decisions: How Can We Help?
By Dan O'Connell
VP, Head of US Marketing
11/15/24
I can only imagine what it must feel like to be responsible for treatment decisions on behalf of someone who lives with Duchenne muscular dystrophy (DMD). Whether that person is yourself or someone you love, the stakes are unspeakably high... Read More
A Guest in Your Home
By Matt Trudeau
President of ITF Therapeutics
11/1/24
We've all had interactions at one point or another with the kind of house guests who aren't welcome – those who impose themselves on the scene with little regard for their hosts, primarily focused on what they can gain from the situation. I firmly believe that that kind of behavior is also bad in business.... Read More
FDA Approval Granted, Access Denied – Now What?
By Stephanie Trafton
Head of US Value & Access
10/4/24
The United States of America is famous for medical innovation. Our country leads the world in the number of new drugs and medical devices that are given the green light by our government. Unfortunately, this does not mean that every approved new... Read More
What Makes an Expert?
By Scott Baver
Vice President, Head of US Medical Affairs
9/23/24
I have been studying neuroscience and working in the field of neuromuscular disease for more than 20 years. I may have the academic degrees and the work experience to qualify as an "expert," but there's no doubt in my mind that the real experts are you... Read More
A Good Day
By Caroline Allen
Head, US Patient Advocacy & Communications
7/25/24
In the long path to new treatments for Duchenne, today is a good day. A new medicine that is designed to interfere with Duchenne’s relentless progression is now officially available in the United States. While I am feeling positive and hopeful because of this... Read More